Keyphrases
Sickle Cell Disease
100%
Hematopoietic Cell Transplantation
73%
Graft-versus-host Disease (GvHD)
72%
Hematopoietic Stem Cell Transplantation
49%
Transplantation
43%
Reduced-intensity Conditioning
40%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
37%
Unrelated Donor
37%
Stem Cell Transplantation
33%
Marrow Transplantation
29%
Unrelated Donor Transplantation
24%
Alemtuzumab
23%
Pediatric
22%
Malignant Disorders
21%
High Risk
18%
Pediatric Patients
18%
Immune Reconstitution
17%
Graft Rejection
17%
Fludarabine
16%
Umbilical Cord Blood
16%
Engraftment
15%
Conditioning Regimen
14%
HLA-matched Donor
13%
Hemoglobinopathies
13%
Hematopoietic Cell Transplant
13%
Melphalan
13%
Late Effects
13%
Reduced Intensity
12%
Donor chimerism
12%
Cell Therapy
12%
Abatacept
12%
Allogeneic Transplantation
12%
Overall Survival
12%
Event-free Survival
11%
Haploidentical Transplantation
11%
Living Donor
11%
Chimerism
10%
Allogeneic Peripheral Blood Stem Cell Transplantation
10%
Bone Marrow Transplantation
10%
Granulocyte Colony-stimulating Factor (G-CSF)
10%
Stem Cell Source
10%
Allogeneic
10%
Disease-free Survival
9%
Preparative Regimen
9%
Marrow
9%
Acute Myeloid Leukemia
9%
Clinical Trials Network
9%
Peripheral Blood Stem Cell Transplantation
9%
Primary Immune Deficiency
9%
Mismatched Related Donor
9%
Medicine and Dentistry
Transplantation
82%
Sickle-Cell Disease
74%
Hematopoietic Stem Cell
70%
Cell Transplantation
67%
Disease
52%
Hematopoietic Stem Cell Transplantation
45%
Stem Cell Therapy
33%
Pediatrics
32%
Graft Versus Host Reaction
30%
Conditioning
21%
Reduced Intensity Conditioning
20%
Cord Blood
17%
Chimera
15%
Engraftment
14%
Hemoglobinopathy
13%
Patient with Sickle Cell Disease
13%
Clinical Trial
12%
Event Free Survival
12%
Late Effect
12%
Cell Therapy
11%
Stem Cell Transplant
9%
Rituximab
9%
B Cell
9%
Overall Survival
9%
Pediatrics Patient
9%
Graft Rejection
9%
Thalassemia
8%
Granulocyte Transfusion
8%
Peripheral Blood Stem Cell
8%
Immunosuppressive Treatment
8%
Stem Cell
8%
Myelodysplastic Syndrome
8%
Allotransplantation
8%
Symptom
7%
Immune Deficiency
7%
Hematologic Malignancy
7%
Quality of Life
7%
Fludarabine
7%
T Cell
6%
Granulocyte Colony Stimulating Factor
6%
Chronic Graft Versus Host Disease
6%
Alemtuzumab
6%
Allogeneic Hematopoietic Stem Cell Transplantation
6%
Neutrophil
6%
Acute Graft Versus Host Disease
6%
Apoplexy
6%
Acute Myeloid Leukemia
6%
Autoimmune Lymphoproliferative Syndrome
6%
Cancer
6%
Graft Failure
6%
Immunology and Microbiology
Hematopoietic Cell
62%
Cell Transplantation
61%
Transplant Procedure
57%
Graft-Versus-Host Disease
54%
Sickle Cell
46%
Conditioning
41%
Hematopoietic Stem Cell Transplantation
31%
Engraftment
25%
Chronic Graft Versus Host Disease
22%
Chimera
21%
Alemtuzumab
20%
Peripheral Blood Stem Cell
17%
Stem Cell Transplant
15%
Stem Cell Transplantation
14%
Stem Cell
14%
Immune Reconstitution
13%
Acute Graft Versus Host Disease
13%
Immunodeficiency
12%
Overall Survival
11%
Allogeneic Peripheral Blood Stem Cell Transplantation
11%
T Cell
11%
Umbilical Cord Blood
9%
Abatacept
9%
Disease Free Survival
9%
Allotransplantation
9%
Lymphocyte
9%
Rituximab
8%
Methotrexate
8%
Myeloid
8%
B Cell
8%
CD34
8%
Neutrophil
8%
Platelet
8%
Granulocyte Colony-Stimulating Factor
7%
Event Free Survival
6%
Regulatory T Cell
6%
Comorbidity
6%
Autoimmune Lymphoproliferative Syndrome
6%
Chronic Granulomatous Disease
5%
Severe Combined Immunodeficiency
5%
Cyclophosphamide
5%
Hemophagocytic Lymphohistiocytosis
5%
Cord Blood Stem Cell Transplantation
5%
Hydroxychloroquine
5%
Granulocyte
5%
CD4
5%
Bone Marrow Transplantation
5%
